Raymond Cheng
Neurology with Special Qualifications in Child Neurology · Atlanta, GANPI 1649345398
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,112 of the $39,690 with a category attached, or 65.8%. 25 manufacturers reported payments, led by Eisai Inc. at 48.0% of the total. Reporting peaked in 2019 at $25,329 and has fallen 98.6% since, to $362 in 2021.
Across 248 payments — averaging $160.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$19K
- Greenwich Biosciences, Inc.$10K
- Supernus Pharmaceuticals, Inc.$6K
- UCB SA$2K
- UCB, Inc.$474
- Sunovion Pharmaceuticals Inc.$340
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,6607%
- Speaking & faculty fees$26,11266%
- Travel & lodging$5,51814%
- Food & beverage$5,39314%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 46 | $19,065 |
| Greenwich Biosciences, Inc. | 42 | $10,215 |
| Supernus Pharmaceuticals, Inc. | 41 | $5,738 |
| UCB SA | 1 | $2,160 |
| UCB, Inc. | 15 | $474 |
| Sunovion Pharmaceuticals Inc. | 16 | $340 |
| Upsher-smith Laboratories LLC | 9 | $256 |
| Tris Pharma Inc | 10 | $211 |
| Ironshore Pharmaceuticals Inc. | 8 | $170 |
| Aquestive Therapeutics, Inc. | 9 | $160 |
| Neos Therapeutics, LP | 13 | $158 |
| Mallinckrodt Enterprises LLC | 5 | $116 |
| Aprecia Pharmaceuticals, LLC | 5 | $110 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $88 |
| SK Life Science, Inc. | 4 | $86 |
| Vertical Pharmaceuticals, LLC | 4 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Shire North American Group Inc | 3 | $49 |
| Adlon Therapeutics L.p. | 3 | $48 |
| Biomarin Pharmaceutical Inc. | 3 | $37 |
| Neurelis, Inc. | 1 | $32 |
| Livanova USA, Inc. | 2 | $31 |
| Natus Medical Incorporated | 1 | $27 |
| AstraZeneca | 1 | $12 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$18,506
- Epidiolex$9,286
- OXTELLAR XR$5,121
How this compares
$39,690 in reported general payments places this provider in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Other neurology with special qualifications in child neurology in Atlanta
- Chaouki KhouryAtlanta$978K
- Han PhanAtlanta$44K
- Sonam BhallaAtlanta$23K
- Cherise FrazierAtlanta$9K
- Howard SchubAtlanta$7K
- Ton de GrauwAtlanta$4K
- Jamika Hallman-CooperAtlanta$2K
- Moira BlackAtlanta$1K
- Jenny LinAtlanta$1K
- Kishore VedalaAtlanta$733
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.